Ingrid Olejarova

We don’t have enough information about this author to calculate their statistics. If you think this is an error let us know.
Learn More
The present study investigated factors associated with therapeutic benefits after autologous bone marrow cell (BMC) therapy in patients with “no-option” critical limb ischemia (CLI). Sixty-two patients with advanced CLI (Rutherford category 5 or 6) not eligible for revascularization were randomized to treatment with 40 ml of autologous BMCs (SmartPreP2) by(More)
  • 1